|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Oxford Immunotec Limited: Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost
6/27/2011 12:44:19 PM
OXFORD, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--The interim findings of the SWITCH study, “Screening healthcare Workers with IGRA vs. TST: Impact on Costs and adHerence to testing”, were presented today at the Association of Professionals in Infection Control and Epidemiology (APIC) annual meeting by Dr. Edward Bernacki, M.D. MPH, Executive Director, Health, Safety and Environment, The Johns Hopkins Health System and University, and Director, Division of Occupational Medicine, Johns Hopkins University, School of Medicine, a principal investigator of the study. The study compared costs and adherence to testing when healthcare workers were screened for tuberculosis (TB) using the tuberculin skin test (TST) or an Interferon Gamma Release Assay (IGRA).
|
|
|
|
|
|
|
|
|
|
|